Director Human Resources

Cardinal Health shares rose over 10% year-to-date but dropped more than 8% since early September. Jim Cramer attributed the decline to investor rotation into AI stocks rather than weak performance, calling the sell-off "stupid" given the company's strong quarterly results. Cardinal Health's fiscal fourth quarter earnings beat analyst estimates with profit per share of $2.91 and full-year guidance of $12.40 to $12.60 exceeding the $12.04 estimate. The pharmaceutical business grew revenue 6% annually to $55.4 billion, driven by demand for branded and specialty drugs. However, Q4 revenue of $63.67 billion missed analyst estimates of $65.03 billion. Management cautioned investors about normalisation ahead, particularly in specialty growth rates. By comparison, Danaher shares fell over 7% year-to-date after deferring $100 million in revenue and cutting its full-year revenue growth guidance.

Heathre Moler appointed Danaher Chief HR Officer. August 26, 2026 Heathre Moler will replace Georgeann Couchara as life science and diagnostics company Danaher's next Chief Human Resources Officer from 1 October 2026 Danaher is set for change at the top of its executive leadership team, with Heathre Moler set to take on the role of Chief HR Officer from 1 October 2026. She will replace Georgeann Couchara, who has held the position since April 2022. Danaher is a global science and technology company focused on biotechnology, diagnostics and life sciences. Its portfolio includes businesses such as Cytiva, Beckman Coulter, Cepheid and Leica Biosystems, providing tools, technologies and services spanning drug development, biomanufacturing and precision diagnostics. Danaher generated around US$25bn in revenue in 2025. Commenting on the appointment, incoming CEO and President of Danaher, Julie Sawyer Montgomery, says, "Heathre is an enterprise-minded leader who understands how talent, culture, leadership and the Danaher Business System connect directly to business performance, and she has earned the trust of teams across multiple Danaher businesses, most recently Diagnostics. "I'm confident she will be a strong partner as we continue strengthening the leadership bench, organisational capability and culture Danaher needs for our next chapter." Danaher: At a glance * US$24.6bn revenue generated by Danaher in 2025, with Diagnostics its largest segment at US$9.9bn. * More than 60,000 associates across more than 15 operating companies and approximately 50 countries. * Three core divisions: Biotechnology, Life Sciences and Diagnostics. * Danaher Business System (DBS) underpins the company's operating model, combining continuous improvement with a focus on growth, lean operations and leadership. Hiring from within. Heathre enters the top HR role at Danaher, having spent more than a decade at the firm. Joining in 2013, she has held HR leadership roles across Danaher's Water Quality Platform, Hach, ChemTreat and Thomson Industries divisions. Previously, she spent more than a decade at ETS-Lindgren, a supplier of energy management solutions for the industrial and commercial markets. Discussing her new role on LinkedIn, Heather writes, "I am honoured to step into this role as CHRO [at] Danaher and grateful for the trust placed in me to help shape its people, culture and leadership in the years ahead. "Thank you to Georgeann Couchara for the strong foundation she leaves behind, and to the many leaders and teams across Danaher who have shaped my journey along the way." "I am honored to step into this role as CHRO [at] Danaher and grateful for the trust placed in me to help shape our people, culture and leadership in the years ahead. " Heathre MolerIncoming Chief HR Officer at Danaher Executive change at Danaher. Heathre's appointment follows Danaher's announcement on 3 August 2026 that Julie Sawyer Montgomery will take on the role of CEO and President from 1 October 2026 - the same date that Heathre's tenure as Chief HR Officer begins. Rainer Blair, who has served as Danaher CEO since 2020, will soon retire from the role but will support the transition as a senior advisor until 31 March 2027. Julie brings nearly 25 years of healthcare, commercial and R&D experience to the role. She joined Danaher in 2017 at Beckman Coulter Diagnostics, becoming President in 2020 after leading commercial operations and R&D. She has since held increasingly senior roles, most recently serving as Danaher Executive Vice President and leading its Diagnostics business from 2023. Under her leadership, Diagnostics nearly doubled revenue from around US$6 billion to US$11 billion, while operating profit roughly tripled. A busy period for Danaher. The appointments of Heathre and Julie come as Danaher prepares for its next phase of growth. The company is coming off a US$24.6bn revenue year in 2025, with Biotechnology, Life Sciences and Diagnostics generating US$7.3bn, US$7.3bn and US$9.9bn respectively. Acquisitions have also been central to Danaher's growth strategy, with a significant proportion of its current revenue coming from businesses acquired over the past decade. Recent deals include the US$9.9bn acquisition of Masimo, completed in June 2026, strengthening its Diagnostics portfolio with patient-monitoring and pulse-oximetry technologies. Earlier major acquisitions include Abcam, Aldevron and Cytiva, expanding Danaher's capabilities across life sciences, genomics and biopharmaceutical manufacturing. The company is also pursuing the acquisition of StatLab, adding further pathology capabilities to Leica Biosystems. Key Danaher partners. CEO: Joe Kiani | HQ: Irvine, California Masimo develops non-invasive patient monitoring technologies, including pulse oximetry, sensors and connectivity platforms. Danaher completed its US$9.9bn acquisition in June 2026, making Masimo a wholly owned subsidiary within its Diagnostics segment while retaining the Masimo brand and standalone operating structure. CEO: Pascal Soriot | HQ: Cambridge, UK AstraZeneca is a global biopharmaceutical company focused on oncology, rare diseases and biopharmaceuticals. In 2025, it partnered with Danaher to develop and commercialise novel diagnostics for precision medicine, initially focusing on digital and computational pathology and AI-assisted algorithms through Danaher's Leica Biosystems. The collaboration aims to improve identification of patients most likely to benefit from targeted therapies. CEO: Abhinav Shashank | HQ: San Francisco, California Innovaccer is a healthcare AI and data company providing platforms designed to connect healthcare data and support clinical decision-making. Danaher announced an investment partnership with Innovaccer in January 2025, combining Danaher's diagnostics expertise with Innovaccer's data and AI capabilities to advance diagnostic and clinical AI solutions. Executives. * Heathre Moler Chief Human Resources Officer (CHRO) Designate * Julie Sawyer Montgomery President Company Portals

BRC Therapeutics appoints biopharma veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy. Aug 24, 2026, 11:00 ET Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ - BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, today announced the appointment of Chandra Ramanathan, Ph.D., M.B.A., as Executive Vice President of Commercialization and Strategy. Ramanathan brings more than 30 years of biopharmaceutical leadership spanning drug development, global product launches, commercialization, and external innovation to BRC as the company advances its pipeline and prepares for its next phase of growth. Ramanathan joins BRC from Danaher Corporation, where he served as Vice President and Global Head of Innovation Hubs and Head of External Innovation, Life Sciences Innovation Group (LSIG) building a funnel of product-oriented partnerships across genomic medicine, diagnostics, LSIG, and biomanufacturing. Prior to Danaher, he spent more than 12 years at Bayer, most recently as Global Head of Pharma R&D Open Innovation, where he chaired the Open Innovation Committee overseeing an annual investment budget of more than $90 million across more than 50 academic and biotech partnerships. While leading Bayer's East Coast Innovation Center in Cambridge, MA, Ramanathan built major partnerships with the Broad Institute, MassGeneral Brigham, and Johns Hopkins University. Earlier in his career, Ramanathan led global launch teams behind two approved therapies (Bosulif(R), Aliqopa(R) and contributed to the launches of Orencia(R), and Sprycel(R) across roles at Wyeth (now Pfizer), Bristol Myers Squibb, and Bayer. As the Head of oncology strategic marketing, he grew Bayer's oncology clinical portfolio from two assets to fifteen over five years. His experience spans the full spectrum of drug development and commercialization: external innovation, product development, companion diagnostics strategy, portfolio and launch planning, and building cross-functional global teams across the U.S., Europe, and Asia. "Chandra has spent his career doing precisely what BRC needs next: progressing promising science into the next phase of clinical development and ultimately into approved medicines that reach patients, based on proven growth strategies and commercial infrastructure to get there," said George Hodgin, Founder and CEO of BRC Therapeutics. "He has led launches at some of the most respected companies in our industry, built innovation engines from the ground up, and has a rare ability to move fluidly between science, innovation strategy, and commercial strategy. As we advance our pipeline in CRPS, AIIA, RLS and additional indications and prepare for our next phase of growth, Chandra's judgment, expertise and experience will be invaluable." "BRC is pursuing something genuinely novel: FDA-regulated cannabinoid medicines for patients with too few good options. The company's foundation is innovative science, a strong intellectual property estate, unique and evolving regulatory approach, and an unwavering drive to make a difference for patients," said Chandra Ramanathan. "I've spent my entire career helping companies bridge early science and commercial reality, and I see that same opportunity here. I'm excited to work alongside George and the BRC team as the company moves toward pivotal trials, new opportunities, and ultimately helping patients." Ramanathan currently serves as Chairperson of the Board of Directors of Nucleate, a nonprofit developing the next generation of biotech entrepreneurs, and holds board and advisory roles with the McLean Hospital, the Johns Hopkins University Innovation, Development & Entrepreneurial Advisory Board and Harvard Business School Blavatnik Fellowship Council. He was also a board member with MassBIO and Chair of the Innovation Committee where he recently finished his 9-year term. He is also an Adjunct Assistant Professor at Tufts University School of Medicine. Ramanathan holds an M.B.A. from Columbia Business School and a Ph.D. in Genomics and Bioinformatics from the University of Georgia. BRC Therapeutics (BRC) is a pharmaceutical company focused on developing innovative therapeutics to deliver relief from pain and other symptoms in chronic conditions. BRC's medicines are multimodal and contain cannabinoids at defined ratios. BRC has developed a pipeline of investigational prescription medicines addressing neurological and inflammatory conditions. Investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS), Restless Legs Syndrome (RLS), and Aromatase Inhibitor-Induced Arthralgia (AIIA) and an additional confidential indication. BRC is registered with the Drug Enforcement Administration and is based in Monterey, CA. Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, including without limitation statements about the development, use, benefits and effects of BRC Therapeutics' (BRC) therapeutic product candidates and related technology, future plans for BRC's business and growth, and expected plans with respect to clinical trials, including the number of patients enrolled and timing of patient enrollment. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "design," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. The forward-looking statements made herein speak only as of the date of this press release and, unless otherwise required by law, BRC does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. SOURCE BRC Therapeutics